Imaging for Transthyretin Amyloid Cardiomyopathy
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to gain a deeper understanding of transthyretin amyloid cardiomyopathy (ATTR-CM), a serious and often overlooked heart condition. Researchers are examining a diverse group of patients suspected of having this condition who underwent a specific imaging test (PYP SPECT) at a Bronx hospital. The study seeks to gather crucial data on how this disease affects individuals from various backgrounds. Individuals who had this imaging test between 2014 and 2023 at Montefiore Medical Center may qualify, provided their echocardiogram (heart ultrasound) records are available. As an unphased study, this trial offers a unique opportunity to contribute to groundbreaking research that could enhance the understanding and treatment of ATTR-CM.
What prior data suggests that this imaging technique is safe for patients?
Research has shown that 99mTc-pyrophosphate (PYP) imaging primarily diagnoses transthyretin amyloid cardiomyopathy (ATTR-CM), a heart condition. Studies have found it effective in identifying this condition. The procedure uses a special substance to highlight problem areas in the heart.
Regarding safety, past reviews and studies have not reported significant side effects specifically linked to the 99mTc-PYP procedure, suggesting it is generally well-tolerated by patients. However, like any imaging technique using these substances, there is some exposure to radiation, but it is usually low and within safe limits. Overall, 99mTc-PYP imaging appears to be a safe option for diagnosing ATTR-CM.12345Why are researchers excited about this trial?
Unlike traditional treatments for transthyretin amyloid cardiomyopathy that often focus on managing symptoms or slowing disease progression, this study involves using 99mTc-pyrophosphate Single Photon Emission Computed Tomography (SPECT) as a diagnostic tool. Researchers are excited about this method because it offers a non-invasive way to detect amyloid deposits in the heart with high specificity. This could lead to earlier and more accurate diagnosis, potentially allowing for timely intervention and better patient outcomes.
What evidence suggests that 99mTc-pyrophosphate SPECT is effective for diagnosing transthyretin amyloid cardiomyopathy?
Research has shown that 99mTc-pyrophosphate (PYP) scans effectively diagnose transthyretin amyloid cardiomyopathy (ATTR-CM). These scans excel in correctly identifying the disease due to their high sensitivity and specificity. They are particularly useful in distinguishing between clear and unclear cases, ensuring an accurate diagnosis. Previous studies have emphasized the importance of 99mTc-PYP imaging in enhancing the accuracy of diagnosing cardiac amyloidosis, which is crucial for better treatment outcomes. Therefore, this diagnostic tool is essential for providing timely and appropriate care for those with ATTR-CM. Participants in this trial will undergo 99mTc-PYP Single Photon Emission Computed Tomography to evaluate its effectiveness in diagnosing suspected transthyretin cardiac amyloidosis.45678
Who Is on the Research Team?
Leandro Slipczuk, MD
Principal Investigator
Montefiore Medical Center
Are You a Good Fit for This Trial?
Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Data Collection
Retrospective evaluation of patients referred for 99mTc-pyrophosphate (PYP) SPECT between 2014 and 2023
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
How Is the Trial Designed?
1
Treatment groups
Experimental Treatment
Patients with suspected transthyretin cardiac amyloidosis referred for 99mTc-pyrophosphate Single Photon Emission Computed Tomography
Find a Clinic Near You
Who Is Running the Clinical Trial?
Montefiore Medical Center
Lead Sponsor
Citations
2025 Update Consensus of 99mTc-Pyrophosphate ...
Key advances in the early diagnosis and treatment of cardiac amyloidosis, highlighting the role of 99mTc-PYP scan in diagnostic accuracy and treatment ...
Equivocal vs Positive Technetium-99m-Pyrophosphate ...
Our patients with equivocal grade 1 scans were not diagnosed with ATTR-CM. They exhibited distinct imaging compared to positive scans.
Biomarkers to Predict Abnormal Technetium-99m ...
Technetium Tc 99m pyrophosphate scintigraphy (99mTc PYP imaging) is a diagnostic tool for transthyretin amyloid cardiomyopathy (ATTR-CM).
Use of Technetium‐99m‐Pyrophosphate Single‐Photon ...
Eplontersen treatment may be effective in patients with hereditary transthyretin amyloid cardiomyopathy, and technetium‐99m‐pyrophosphate single ...
Reproducibility of 99mTc-pyrophosphate SPECT/CT cardiac ...
SPECT/CT MBP ratios at both 1 hr & 3 hrs have high sensitivity and specificity for diagnosing ATTR cardiac amyloid as defined by recent imaging consensus ...
99mTechnetium‐pyrophosphate scintigraphy
In this review, we discuss the utility of 99m Tc‐labelled bone radiotracer scintigraphy for the early diagnosis of ATTR‐CM based on published literature.
99mTc-Pyrophosphate Scintigraphy for Differentiating Light ...
99m Tc-PYP cardiac imaging distinguishes AL from ATTR cardiac amyloidosis and may be a simple, widely available method for identifying subjects with ATTR ...
Use of technetium-99m-pyrophosphate single-photon ...
Our results demonstrated a significant decrease in volumetric H/L ratio in hereditary ATTR-CA patients receiving RNA interference therapeutics.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.